The chemical class referred to as U2AF35 inhibitors represents a distinctive group of organic compounds designed to modulate the activity of U2AF35, a critical component of the spliceosome complex involved in pre-mRNA splicing. These inhibitors share a common mechanism of action, which involves disrupting the interaction between U2AF35 and pre-mRNA molecules during splice site recognition. U2AF35 plays a pivotal role in determining the precise location of splicing events within pre-mRNA sequences, thereby influencing the final gene expression outcomes. U2AF35 inhibitors are meticulously crafted to selectively bind to U2AF35 or its binding interface on pre-mRNA, thereby perturbing the essential interactions required for proper splice site identification. The chemical structures within the U2AF35 inhibitors class are carefully designed to fit the spatial conformation of U2AF35's binding domains, enabling them to hinder the recognition of splice sites. This interference with U2AF35's binding activity can lead to altered splicing patterns, impacting the diversity of messenger RNA transcripts generated from pre-mRNA. The uniqueness of this class stems from the precise interplay between the inhibitors' structural features and the specific molecular interactions they target. This allows researchers to dissect the intricate process of pre-mRNA splicing and decipher the regulatory mechanisms governed by U2AF35.
The discovery and characterization of U2AF35 inhibitors have significantly advanced our understanding of the molecular intricacies underlying splicing regulation. Researchers employ these inhibitors as potent tools to investigate the downstream consequences of interfering with U2AF35-mediated splicing events, shedding light on the broader implications for gene expression. The chemical class of U2AF35 inhibitors has enabled breakthrough insights into the dynamic interplay between splicing factors and pre-mRNA, fostering a deeper appreciation for the role of U2AF35 in shaping the intricacies of cellular function. Through their application, scientists continue to unravel the complexity of pre-mRNA splicing mechanisms and their impact on gene expression landscapes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Pladienolide B | 445493-23-2 | sc-391691 sc-391691B sc-391691A sc-391691C sc-391691D sc-391691E | 0.5 mg 10 mg 20 mg 50 mg 100 mg 5 mg | $299.00 $5699.00 $11099.00 $25500.00 $66300.00 $2875.00 | 63 | |
A natural product isolated from Streptomyces platensis, pladienolide B inhibits U2AF35 binding to pre-mRNA, affecting splice site recognition and alternative splicing patterns. | ||||||
Herboxidiene | 142861-00-5 | sc-506378 | 1 mg | $1009.00 | ||
Another natural compound, herboxidiene, inhibits U2AF35 by disrupting its interaction with the polypyrimidine tract of pre-mRNA. This interference affects splicing outcomes. | ||||||
Spliceostatin A | 391611-36-2 | sc-507481 | 1 mg | $1800.00 | ||
Isolated from the bacterium Burkholderia sp., spliceostatin A inhibits U2AF35 binding to pre-mRNA, causing aberrant splicing events and influencing gene expression. | ||||||
Sinefungin | 58944-73-3 | sc-203263 sc-203263B sc-203263C sc-203263A | 1 mg 100 mg 1 g 10 mg | $271.00 $5202.00 $40368.00 $704.00 | 4 | |
Although primarily known as a S-adenosylmethionine analog and methyltransferase inhibitor, sinefungin also exhibits U2AF35 inhibition properties, affecting splicing. | ||||||
FR901464 | 146478-72-0 | sc-507352 | 5 mg | $1800.00 | ||
An antitumor agent that inhibits U2AF35 binding to RNA. FR901464-induced splicing changes can lead to growth inhibition of cancer cells. | ||||||
Plumbagin | 481-42-5 | sc-253283 sc-253283A | 100 mg 250 mg | $52.00 $62.00 | 6 | |
While mainly recognized for its anticancer properties, plumbagin also exhibits U2AF35 inhibition activity, affecting pre-mRNA splicing and gene expression. | ||||||